jps.21523

[ Pobierz całość w formacie PDF ]

Polyanhydrides: Synthesis and characterization. the immunogenicity and efficacy of intranasally
Adv Polym Sci 107:94 141. administered vaccines. Vaccine 21:3837 3844.
168. Seidel JO, Uhrich KE, Laurencin CT, Langer R. 181. Illum L, Farraj NF, Davis SS. 1994. Chitosan as a
1996. Erosion of poly(anhydride-co-imides): A pre- novel nasal delivery system for peptide drugs.
liminary mechanistic study. J Appl Polym Sci 62: Pharm Res 11:1186 1189.
1277 1283. 182. Alpar HO, Somavarapu S, Atuah KN, Bramwell
169. Shen E, Patel P, Uhrich K, Narasimhan B. 1999. VW. 2005. Biodegradable mucoadhesive parti-
Morphological characterization of erodible poly- culates for nasal and pulmonary antigen and
mer carriers for drug release. Proc Int Symp Con- DNA delivery. Adv Drug Deliv Rev 57:411 430.
trol Rel Bioact Mater 26:717 718. 183. Boonyo W, Junginger HE, Waranuch N, Polnok A,
170. Shen E, Pizsczek R, Dziadul B, Narasimhan B. Pitaksuteepong T. 2007. Chitosan and trimethyl
2001. Microphase separation in bioerodible co- chitosan chloride (TMC) as adjuvants for inducing
polymers for drug delivery. Biomaterials 22:201 immune responses to ovalbumin in mice following
210. nasal administration. J Control Release 121:168
171. Erdmann L, Macedo B, Uhrich KE. 2000. Degrad- 175.
able poly(anhydride ester) implants: Effects of 184. Singh M, O Hagan D. 1998. The preparation and
localized salicylic acid release on bone. Biomater- characterization of polymeric antigen delivery
ials 21:2507 2512. systems for oral administration. Adv Drug Deliv
172. Fu J, Fiegel J, Krauland E, Hanes J. 2002. New Rev 34:285 304.
polymeric carriers for controlled drug delivery 185. Heritage PL, Loomes LM, Jianxiong J, Brook MA,
following inhalation or injection. Biomaterials Underdown BJ, McDermott MB. 1996. Novel poly-
23:4425 4433. mer-grafted starch microparticles for mucosal
173. Mathiowitz E, Ron E, Mathiowitz G, Amato C, delivery of vaccines. Immunology 88:162 168.
Langer R. 1990. Morphological characterization 186. Stertman L, Strindelius L, Sjoholm I. 2004. Starch
of bioerodible polymers. 1. crystallinity of poly- microparticles as an adjuvant in immunisation:
anhydride copolymers. Macromolecules 23:3212 Effect of route of administration on the immune
3218. response in mice. Vaccine 22:2863 2872.
174. Torres MP, Determan A, Mallapragada SK, 187. Vassilev VP, DeFife KM, Landis GC, Mendy J,
Narasimhan B. 2006. Polyanhydrides. In: Lee S, Minev BR, Cantwell MJ, Carpenter KW, Turnell
editor. Encyclopedia of chemical processing. New WG. 2005. Inducing an immune response using a
York: Marcel Dekker. pp 2247 2257. novel poly(ester-amide) co-polymer delivery plat-
175. Tamada J, Langer R. 1992. The development of form. Drug Deliv Technol 5:54 59.
polyanhydrides for drug delivery applications. 188. Greenland JR, Letvin NL. 2007. Chemical adju-
J Biomater Sci Polym Ed 3:315 353. vants for plasmid DNA vaccines. Vaccine 25:3731
176. Determan AS, Trewyn BG, Lin VS, Nilsen-Hamil- 3741.
ton M, Narasimhan B. 2004. Encapsulation, 189. Alpar HO, Ozsoy Y, Bowen J, Eyles JE, Conway
stabilization, and release of BSA-FITC from poly- BR, Williamson ED. 1997. Potential of particulate
anhydride microspheres. J Control Release 100:97 carriers for the mucosal delivery of DNA vaccines.
109. Biochem Soc Trans 25:337S.
177. Shu Q, Hillard MA, Bindon BM, Duan E, Xu Y, 190. Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants:
Bird SH, Rowe JB, Oddy VH, Gill HS. 2000. Current state and future trends. Immunol Cell
Effects of various adjuvants on efficacy of a vaccine Biol 82:488 496.
against Streptococcus bovis and Lactobacillus spp 191. Newman KD, Elamanchili P, Kwon GS, Samuel J.
in cattle. Am J Vet Res 61:839 843. 2002. Uptake of poly(D,L-lactic-co-glycolic acid)
178. Wedlock DN, Keen DL, McCarthy AR, Andersen microspheres by antigen-presenting cells in vivo.
P, Buddle BM. 2002. Effect of different adjuvants J Biomed Mater Res 60:480 486.
on the immune responses of cattle vaccinated with 192. Kim W, Lee W, Ryoo J, Kim S, Kim J, Youn J, Min
Mycobacterium tuberculosis culture filtrate pro- S, Bae E, Hwang S, Park S, Cho C, Park J, Kim H.
teins. Vet Immunol Immunopathol 86:79 88. 2002. Suppression of collagen-induced arthritis by
179. Ogawa T, Asai Y, Sakamoto H, Yasuda K. 2006. single administration of poly(lactic-co-glycolic
Oral immunoadjuvant activity of Lactobacillus acid) nanoparticles entrapping type II collagen:
casei subsp. casei in dextran-fed layer chickens. A novel treatment strategy for induction of oral
Br J Nutr 95:430 434. tolerance. Arthritis Rheum 46:1109 1120.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 4, APRIL 2009
1314 WILSON-WELDER ET AL.
193. Conway MA, Madrigal-Estebas L, McClean S, MSP2 long synthetic peptides in mice. Vaccine 25:
Brayden DJ, Mills KH. 2001. Protection against 877 885.
Bordetella pertussis infection following parenteral 203. Gupta RK, Singh M, O Hagan DT. 1998. Poly(lac-
or oral immunization with antigens entrapped in tide-co-glycolide) microparticles for the develop-
biodegradable particles: Effect of formulation and ment of single-dose controlled-release vaccines.
route of immunization on induction of Th1 and Adv Drug Deliv Rev 32:225 246.
Th2 cells. Vaccine 19:1940 1950. 204. O Brien CN, Guidry AJ. 1996. Formulation of
194. Gupta RK, Alroy J, Alonso MJ, Langer R, Siber poly(DL-lactide-co-glycolide) microspheres and
GR. 1997. Chronic local tissue reactions, long- their ingestion by bovine leukocytes. J Dairy Sci
term immunogenicity and immunologic priming 79:1954 1959.
of mice and guinea pigs to tetanus toxoid encap- 205. Waeckerle-Men Y, Scandella E, Allmen EU-v,
sulated in biodegradable polymer microspheres Ludewig B, Gillessen S, Merkle HP, Gander B,
composed of poly lactide-co-glycolide polymers. Groettrup M. 2004. Phenotype and functional ana-
Vaccine 15:1716 1723. lysis of human monocyte-derived dendritic
195. Evans JT, Ward JR, Kern J, Johnson ME. cells loaded with biodegradable poly(lactide-co-
2004. A single vaccination with protein- glycolide) microspheres for immunotherapy.
microspheres elicits a strong CD8 T-cell-mediated J Immunol Methods 287:109 124.
immune response against Mycobacterium 206. Lacasse FX, Filion MC, Phillips NC, Escher E,
tuberculosis antigen Mtb8.4. Vaccine 22:1964 McMullen JN, Hildgen P. 1998. Influence of
1972. surface properties at biodegradable microsphere
196. Men Y, Thomasin C, Merkle HP, Gander B, Cor- surfaces: Effects on plasma protein adsorption and
radin G. 1995. A single administration of tetanus phagocytosis. Pharm Res 15:312 317.
toxoid in biodegradable microspheres elicits T cell 207. Pitaksuteepong T, Davies N, Baird M, Rades T.
and antibody responses similar or superior to 2004. Uptake of antigen encapsulated in poly-
those obtained with aluminum hydroxide. Vaccine ethylcyanoacrylate nanoparticles by D1-dendritic
13:683 689. cells. Pharmazie 59:134 142. [ Pobierz całość w formacie PDF ]

Pokrewne